DECCAN HEALTH CARE LTD.

NSE : NABSE : 542248ISIN CODE : INE452W01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE26.00-0.54 (-2.03 %)
PREV CLOSE ( ) 26.54
OPEN PRICE ( ) 26.99
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 87217
TODAY'S LOW / HIGH ( )25.76 26.99
52 WK LOW / HIGH ( ) 23.142
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2023Mar2022Mar2021
Profit Before Tax5.1739.435.19
Adjustment7.83-17.7915.66
Changes In working Capital-76.88-24.85-17.27
Cash Flow after changes in Working Capital-63.88-3.223.58
Cash Flow from Operating Activities-66.06-5.732.19
Cash Flow from Investing Activities2.51-0.49-0.72
Cash Flow from Financing Activities51.210.67-3.70
Net Cash Inflow / Outflow-12.34-5.55-2.23
Opening Cash & Cash Equivalents26.6832.2334.45
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANA
Effect of Foreign Exchange FluctuationsNANANA
Closing Cash & Cash Equivalent14.3426.6832.23

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.